{
    "articles": [
        {
            "url": "https://www.businesswire.com/news/home/20201124005971/en/Urovant-Sciences-Announces-Topline-Data-from-Phase-2a-Study-of-Vibegron-for-the-Treatment-of-Irritable-Bowel-Syndrome-IBS-Pain-Did-Not-Meet-Primary-Endpoint",
            "url_mobile": "",
            "title": "Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome ( IBS ) Pain Did Not Meet Primary Endpoint",
            "seendate": "20201125T014500Z",
            "socialimage": "https://mms.businesswire.com/media/20201124005971/en/771690/23/UrovantSciences_RGB.jpg",
            "domain": "businesswire.com",
            "language": "English",
            "sourcecountry": "United States"
        },
        {
            "url": "https://www.finanznachrichten.de/nachrichten-2020-10/50896789-urovant-sciences-announces-co-promotion-agreement-for-vibegron-with-sunovion-pharmaceuticals-004.htm",
            "url_mobile": "",
            "title": "Urovant Sciences Announces Co - Promotion Agreement for Vibegron with Sunovion Pharmaceuticals",
            "seendate": "20201007T124500Z",
            "socialimage": "https://www.finanznachrichten.de/chart-sumitomo-dainippon-pharma-co-ltd-aktie-intraday-frankfurt.png",
            "domain": "finanznachrichten.de",
            "language": "English",
            "sourcecountry": "Germany"
        },
        {
            "url": "https://www.finanznachrichten.de/nachrichten-2020-11/51334066-urovant-sciences-announces-topline-data-from-phase-2a-study-of-vibegron-for-the-treatment-of-irritable-bowel-syndrome-ibs-pain-did-not-meet-primary-004.htm",
            "url_mobile": "",
            "title": "Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome ( IBS ) Pain Did Not Meet Primary Endpoint",
            "seendate": "20201124T213000Z",
            "socialimage": "https://www.finanznachrichten.de/kein-chart.png",
            "domain": "finanznachrichten.de",
            "language": "English",
            "sourcecountry": "Germany"
        },
        {
            "url": "https://www.businesswire.com/news/home/20201119005443/en/Urovant-Sciences-Announces-Positive-Clinical-Efficacy-and-Safety-Data-from-Vibegron-EMPOWUR-Long-Term-Extension-Study",
            "url_mobile": "",
            "title": "Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study",
            "seendate": "20201119T144500Z",
            "socialimage": "https://mms.businesswire.com/media/20201119005443/en/771690/23/UrovantSciences_RGB.jpg",
            "domain": "businesswire.com",
            "language": "English",
            "sourcecountry": "United States"
        },
        {
            "url": "https://www.fool.com/earnings/call-transcripts/2020/11/02/urovant-sciences-ltd-urov-q2-2020-earnings-call-tr/?source=iedfolrf0000001",
            "url_mobile": "https://www.fool.com/amp/earnings/call-transcripts/2020/11/02/urovant-sciences-ltd-urov-q2-2020-earnings-call-tr/",
            "title": "UROVANT SCIENCES LTD ( UROV ) Q2 2020 Earnings Call Transcript",
            "seendate": "20201103T120000Z",
            "socialimage": "",
            "domain": "fool.com",
            "language": "English",
            "sourcecountry": "United States"
        },
        {
            "url": "https://www.finanznachrichten.de/nachrichten-2020-11/51291681-urovant-sciences-announces-positive-clinical-efficacy-and-safety-data-from-vibegron-empowur-long-term-extension-study-004.htm",
            "url_mobile": "",
            "title": "Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study",
            "seendate": "20201119T133000Z",
            "socialimage": "https://cts.businesswire.com/ct/CT?id=bwnews&sty=20201119005443r1&sid=gefi2&distro=ftp",
            "domain": "finanznachrichten.de",
            "language": "English",
            "sourcecountry": "Germany"
        },
        {
            "url": "https://www.finanznachrichten.de/nachrichten-2020-09/50645294-urovant-sciences-to-present-at-the-h-c-wainwright-co-annual-global-investment-conference-004.htm",
            "url_mobile": "",
            "title": "Urovant Sciences to Present at the H . C . Wainwright & Co . Annual Global Investment Conference",
            "seendate": "20200908T123000Z",
            "socialimage": "https://cts.businesswire.com/ct/CT?id=bwnews&sty=20200908005383r1&sid=gefi2&distro=ftp",
            "domain": "finanznachrichten.de",
            "language": "English",
            "sourcecountry": "Germany"
        },
        {
            "url": "http://www.digitaljournal.com/pr/4884995",
            "url_mobile": "",
            "title": "Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study - Press Release",
            "seendate": "20201119T133000Z",
            "socialimage": "",
            "domain": "digitaljournal.com",
            "language": "English",
            "sourcecountry": "United States"
        },
        {
            "url": "http://www.digitaljournal.com/pr/4855550",
            "url_mobile": "",
            "title": "Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results - Press Release",
            "seendate": "20201027T123000Z",
            "socialimage": "",
            "domain": "digitaljournal.com",
            "language": "English",
            "sourcecountry": "United States"
        },
        {
            "url": "https://www.fxstreet.com/news/urovant-sciences-ltd-urov-stock-price-trades-flat-to-start-the-week-after-sumitovant-buyout-202011171217",
            "url_mobile": "https://www.fxstreet.com/amp/news/urovant-sciences-ltd-urov-stock-price-trades-flat-to-start-the-week-after-sumitovant-buyout-202011171217",
            "title": "Urovant Sciences Ltd ( UROV Stock ) price trades flat to start the week after Sumitovant buyout",
            "seendate": "20201117T130000Z",
            "socialimage": "https://editorial.fxstreet.com/images/Markets/Equities/Nasdaq/new-york-stock-exchange-18404353_Large.jpg",
            "domain": "fxstreet.com",
            "language": "English",
            "sourcecountry": "China"
        },
        {
            "url": "https://www.benzinga.com/general/biotech/20/11/18561828/attention-biotech-investors-mark-your-calendar-for-december-pdufa-dates",
            "url_mobile": "https://amp.benzinga.com/amp/content/18561828",
            "title": "iShares NASDAQ Biotechnology Index Fund ( NASDAQ : IBB ), ( ABBV ) - Attention Biotech Investors : Mark Your Calendar For December PDUFA Dates",
            "seendate": "20201128T204500Z",
            "socialimage": "",
            "domain": "benzinga.com",
            "language": "English",
            "sourcecountry": "United States"
        },
        {
            "url": "https://www.finanznachrichten.de/nachrichten-2020-11/51235643-astrazeneca-s-repurposed-covid-19-drug-fails-navb-on-watch-cvac-rallies-on-storage-advantage-of-cvncov-020.htm",
            "url_mobile": "",
            "title": "AstraZeneca Repurposed COVID - 19 Drug Fails , NAVB On Watch , CVAC Rallies On Storage Advantage Of CVnCoV",
            "seendate": "20201113T083000Z",
            "socialimage": "https://www.finanznachrichten.de/chart-astrazeneca-plc-aktie-intraday-xetra.png",
            "domain": "finanznachrichten.de",
            "language": "English",
            "sourcecountry": "Germany"
        }
    ]
}